F0778
Felbamate
NMDA glutamate receptor antagonist
Synonym(s):
2-Phenyl-1,3-propanediol dicarbamate
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C11H14N2O4
CAS Number:
Molecular Weight:
238.24
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
247-001-4
MDL number:
Quality level:
Product Name
Felbamate,
Quality Level
solubility
alcohol: soluble
SMILES string
NC(=O)OCC(COC(N)=O)c1ccccc1
InChI
1S/C11H14N2O4/c12-10(14)16-6-9(7-17-11(13)15)8-4-2-1-3-5-8/h1-5,9H,6-7H2,(H2,12,14)(H2,13,15)
InChI key
WKGXYQFOCVYPAC-UHFFFAOYSA-N
Gene Information
human ... GRIN1(2902), GRIN2A(2903), GRIN2B(2904), GRIN2C(2905), GRIN2D(2906), GRIN3A(116443), GRIN3B(116444)
Biochem/physiol Actions
Anticonvulsant agent that is an allosteric antagonist at the NR2B subunit of the NMDA glutamate receptor; also has γ-aminobutyric acid (GABAA) receptor agonist properties.
Still not finding the right product?
Explore all of our products under Felbamate
Storage Class
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Related Content
I E Leppik
Epilepsia, 36 Suppl 2, S66-S72 (1995-01-01)
After the first year of clinical experience, felbamate (FBM) appears to be a valuable antiepileptic drug (AED) for the treatment of intractable epilepsy. However, many patients experience side effects that may discourage continued usage. These may be decreased by using
Mary L Zupanc et al.
Pediatric neurology, 42(6), 396-403 (2010-05-18)
The antiepileptic drug felbamate has demonstrated efficacy against a variety of seizure types in the pediatric population, particularly seizures associated with Lennox-Gastaut syndrome. Postmarketing experience, however, revealed serious idiosyncratic adverse effects not observed during clinical trials, including aplastic anemia and
P Glue et al.
Clinical pharmacokinetics, 33(3), 214-224 (1997-10-07)
This article provides an analysis of the degree of agreement between in vivo interaction studies performed in patients with epilepsy and healthy individuals, and in vitro studies which identified the cytochromes P450 (CYP) inhibited by felbamate and those involved in